【24h】

Motexafin lutetium in graft coronary artery disease

机译:移植冠状动脉疾病中的MOTEXAFIN LUTETIUM

获取原文

摘要

Graft coronary artery disease (GCAD) is the chief complication following cardiac transplantation. Presently, there are limited treatment options. Insights into more expedient diagnosis and amelioration, if only partially, of GCAD are fervently sought. The selectivity of Antrin Injection (Lu-Tex) with subsequent photoactivation has been evaluated in several preclinical atherosclerosis models. The inhibitory effect of Lu-Tex induced photosensitization was demonstrated with human bypass coronary smooth muscle cells. The biodistribution of Lu-Tex was evaluated in a rat model of heterotopic cardiac allografts 60 days following transplantation. Lu-Tex was retained in the cardiac allograft, exhibiting a five-fold increase in retention between the allograft and native heart. These findings lead us to suggest that further studies are warranted to ascertain the merits of Lu-Tex for the diagnosis and possible attenuation of chronic graft vascular disease.
机译:移植冠状动脉疾病(GCAD)是心脏移植后的主要并发症。目前,治疗方案有限。在GCAD的情况下,只有有利的诊断和改善的洞察力都是热烈的诊断和改善。在几种临床前动脉粥样硬化模型中,评估了随后的光激活的antrin注射(Lu-tex)的选择性。 Lu-Tex诱导的光敏的抑制作用用人旁路冠状动脉平滑肌细胞进行了证明。移植后60天的异位心脏同种异体移植物的大鼠模型中评估了Lu-Tex的生物分布。 Lu-Tex保留在心脏同种异体移植物中,表现出同种异体移植和本地心脏之间的滞留下的五倍。这些调查结果导致我们建议有必要进一步研究,以确定Lu-Tex的优点,用于诊断和可能衰减慢性接枝血管疾病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号